Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias
Publication
, Other
Zhang, W; Li, L; Muftuoglu, M; Basyal, M; Togashi, N; Iwanaga, K; Tanzawa, F; Numata, M; Bixby, DL; Erba, HP; Podoltsev, N; Schiller, GJ ...
July 15, 2025
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, W., Li, L., Muftuoglu, M., Basyal, M., Togashi, N., Iwanaga, K., … Andreeff, M. (2025). Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias. https://doi.org/10.1158/1078-0432.29567912
Zhang, Weiguo, Li Li, Muharrem Muftuoglu, Mahesh Basyal, Noriko Togashi, Koichi Iwanaga, Fumie Tanzawa, et al. “Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias,” July 15, 2025. https://doi.org/10.1158/1078-0432.29567912.
Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, et al. Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias. 2025.
Zhang, Weiguo, et al. Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias. 15 July 2025. Crossref, doi:10.1158/1078-0432.29567912.
Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar P, Lesegretain A, Isoyama T, Seki T, Daver N, Andreeff M. Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias. 2025.